Sanofi Pasteur
This sponsor has funded 4 studies across 8 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 13766 | Finalised | Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case: Incidence rates of pertussis and pertussis related outcomes of... | Yes | Yes |
| 25599 | Ongoing | Case-control study based on hospitals about seasonal influenza vaccine effectiveness to avoid income associated with laboratory-confirmed influenza... | Yes | No |
| 28947 | Ongoing | Post-Authorization Safety Study Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine (DNG15-Post Authorisation safety Surveillance study) | No | No |
| 36560 | Planned | INFLUENZA AND ACUTE MYOCARDIAL INFARCTION IN THE COMMUNITY OF MADRID: A RETROSPECTIVE ECOLOGICAL TIME-SERIES STUDY (2013-2018) (FLU-AMI-ECO) | No | No |
PAS by Risk Management Plan (RMP) requirement
Sanofi Pasteur
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Sanofi Pasteur
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Sanofi Pasteur
8 Study countries specified are the following:
- Brazil
- Denmark
- Italy
- Mexico
- Netherlands
- Philippines
- Spain
- Sweden